Garovoy MR - Search Results

1

Subcutaneous efalizumab is not effective in the treatment of alopecia areata.

Price VH, Hordinsky MK, Olsen EA, Roberts JL, Siegfried EC, Rafal ES, Korman NJ, Altrabulsi B, Leung HM, Garovoy MR, Caro I, Whiting DA. Price VH, et al. Among authors: garovoy mr. J Am Acad Dermatol. 2008 Mar;58(3):395-402. doi: 10.1016/j.jaad.2007.10.645. J Am Acad Dermatol. 2008. PMID: 18280336 Clinical Trial.

2

HLA class II antigen associations help to define two types of alopecia areata.

Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. Colombe BW, et al. Among authors: garovoy mr. J Am Acad Dermatol. 1995 Nov;33(5 Pt 1):757-64. J Am Acad Dermatol. 1995. PMID: 7593774

3

Efalizumab for the treatment of psoriatic arthritis.

Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Papp KA, et al. J Cutan Med Surg. 2007 Mar-Apr;11(2):57-66. doi: 10.2310/7750.2007.00006. J Cutan Med Surg. 2007. PMID: 17374316 Clinical Trial.

4

Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.

Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, Garovoy M, Kwon P, Pariser DM; Efalizumab Study Group. Menter A, et al. Int J Dermatol. 2007 Jun;46(6):637-48. doi: 10.1111/j.1365-4632.2007.03158.x. Int J Dermatol. 2007. PMID: 17550570 Clinical Trial.

5

Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. Ng CM, et al. Among authors: garovoy mr. Pharm Res. 2005 Jul;22(7):1088-100. doi: 10.1007/s11095-005-5642-4. Epub 2005 Jul 22. Pharm Res. 2005. PMID: 16028009 Clinical Trial.

6

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.

Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. Papp K, et al. Among authors: garovoy mr. J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.

7

A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.

Vincenti F, Mendez R, Pescovitz M, Rajagopalan PR, Wilkinson AH, Butt K, Laskow D, Slakey DP, Lorber MI, Garg JP, Garovoy M. Vincenti F, et al. Am J Transplant. 2007 Jul;7(7):1770-7. doi: 10.1111/j.1600-6143.2007.01845.x. Am J Transplant. 2007. PMID: 17564637 Free article. Clinical Trial.

8

An improved method for the detection of soluble interleukin 2 receptors in liver transplant recipients by flow cytometry.

Cohen N, Gumbert M, Birnbaum J, Lim VL, Falco D, Ascher N, Roberts J, Garovoy MR. Cohen N, et al. Among authors: garovoy mr. Transplantation. 1991 Feb;51(2):417-21. doi: 10.1097/00007890-199102000-00028. Transplantation. 1991. PMID: 1899733

9

Comparison of ELISA and a flow cytometric method in the daily monitoring of soluble interleukin 2 receptors in liver transplant recipients.

Cohen N, Roberts J, Gumbert M, Birnbaum J, Lim VL, Falco D, Ascher N, Garovoy MR. Cohen N, et al. Among authors: garovoy mr. Transplant Proc. 1991 Feb;23(1 Pt 2):1426-7. Transplant Proc. 1991. PMID: 1989253 No abstract available.

10

Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Gottlieb AB, et al. Arch Dermatol. 2002 May;138(5):591-600. doi: 10.1001/archderm.138.5.591. Arch Dermatol. 2002. PMID: 12020219 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page